trigger_id,patient_id,hcp_id,trigger_timestamp,trigger_type,priority,confidence_score,lead_time_days,expiration_date,delivery_channel,delivery_status,delivery_timestamp,acceptance_status,action_taken,false_positive_flag,trigger_reason,recommended_action,outcome_tracked,outcome_value,previous_trigger_id,change_type,change_reason,change_failed,data_split
TRG000000000000000000000001,PAT00000001,HCP00000001,2025-11-01T09:00:00Z,treatment_switch,high,0.850,14,2025-11-15,email,delivered,2025-11-01T09:05:00Z,accepted,Scheduled follow-up visit,false,Patient showing suboptimal response to current therapy,Discuss Remibrutinib as alternative BTK inhibitor,true,0.780,,new,,false,train
TRG000000000000000000000002,PAT00000002,HCP00000002,2025-11-03T14:00:00Z,adherence_risk,critical,0.920,7,2025-11-10,in_app,delivered,2025-11-03T14:02:00Z,accepted,Called patient for medication review,false,Missed refill detected - 5 days overdue,Contact patient regarding Fabhalta refill compliance,true,0.650,,new,,false,train
TRG000000000000000000000003,PAT00000003,HCP00000003,2025-11-05T11:00:00Z,new_patient,medium,0.720,21,2025-11-26,digital,delivered,2025-11-05T11:10:00Z,pending,,false,Newly diagnosed HR+/HER2- breast cancer patient,Consider Kisqali + aromatase inhibitor as first-line,false,,,new,,false,validation
TRG000000000000000000000004,PAT00000004,HCP00000004,2025-11-08T16:00:00Z,dosage_optimization,low,0.580,30,2025-12-08,email,delivered,2025-11-08T16:05:00Z,rejected,,true,Dosage adjustment suggestion based on lab results,Review current dosage efficacy,true,0.120,,new,,false,test
TRG000000000000000000000005,PAT00000001,HCP00000001,2025-11-15T10:00:00Z,treatment_switch,high,0.890,14,2025-11-29,email,delivered,2025-11-15T10:03:00Z,accepted,Initiated Remibrutinib prescription,false,Updated evidence from recent follow-up,Proceed with Remibrutinib initiation,true,0.920,TRG000000000000000000000001,escalation,Patient visit confirmed suboptimal response,false,holdout
